How Biotech Startups Are Using Generative AI to Design Antibodies

Episode 54 of Biotech Business with Fexingo explores how generative AI is transforming antibody design. Lucas and Luna dive into the story of startup Absci, which used a generative model to create a novel antibody against a difficult target—HER2—in just 23 days. They discuss the difference between traditional phage display and AI-driven de novo design, the challenges of computational vs. experimental validation, and why Big Pharma is paying attention. The hosts also touch on the broader shift from AI-assisted discovery to AI-driven creation in biotech. A concrete look at how protein language models and diffusion models are moving beyond small molecules into biologics, and what it means for the speed and cost of bringing new drugs to patients. #GenerativeAI #AntibodyDesign #Biotech #AbSci #ProteinEngineering #DrugDiscovery #Biologics #HealthcareInnovation #AIinBiotech #LifeSciences #Startups #Business #Technology #FexingoBusiness #BusinessPodcast #BiotechBusiness #MachineLearning #Therapeutics Keep every episode free: buymeacoffee.com/fexingo